多中心随机优效性临床试验:无创磁刺激膈神经保留机械通气早期患者膈肌厚度——STIMIT ACTIVATOR 1关键性试验
STIMIT ACTIVATOR 1是一项在美加4个ICU开展的多中心随机优效性试验,计划纳入40例机械通气早期患者,随机接受标准治疗或每日30分钟无创磁刺激膈神经最长10天,主要终点为第10天、拔管或死亡时(以先发生者为准)膈肌厚度变化,旨在评估该技术的可行性、安全性和保留膈肌厚度的效果。
要点
- 机械通气诱导的膈肌功能障碍(VIDD)发生率高达60%,可延长通气依赖。
- 该试验为首次评估无创膈神经刺激器保留膈肌厚度的可行性、安全性和有用性。
- 主要终点为第10天、拔管或死亡时(以先发生者为准)膈肌厚度变化,计划样本量40例。
核心结论
- STIMIT ACTIVATOR试验旨在阐明无创膈神经刺激是否可行、安全并保留膈肌厚度。
- 达到主要终点将证明其在临床实践中预防通气患者膈肌萎缩的适用性。
研究设计与样本
- 多中心随机临床试验,在美加4个ICU开展,计划纳入40例(每组20例)。
- 纳入标准:年龄>21岁、机械通气48小时内、预计至少继续通气48小时。
- 排除标准:有膈神经刺激禁忌、严重慢性肺病或无法超声测量膈肌厚度。
- 随机分为标准治疗(对照)或每日30分钟无创膈神经刺激至入组后10天(干预)。
主要发现
- 主要有效性终点为第10天、拔管或死亡时(以先发生者为准)膈肌厚度变化。
- 次要终点包括第4天膈肌厚度变化、拔管前最大吸气压及至快速浅呼吸指数(RSBI)<105的时间。
- 安全性目标包括器械或操作相关不良事件(SAE)的比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ventilator-induced diaphragmatic dysfunction (VIDD) occurs in up to 60% of mechanically ventilated patients and prolongs ventilatory dependance. The consequences of VIDD are muscle atrophy, reduction of strength, and injury of muscle fibers. Atrophy and contractile activity of the diaphragm can be estimated by ultrasound muscle thickness and thickening fraction. Prior experience demonstrates invasive electrical stimulation of the diaphragm helps preserve muscle thickness. This is the first study on a non-invasive phrenic nerve stimulator that aims to assess its feasibility, safety, and usefulness in preserving diaphragm thickness. METHODS: A multi-center randomized clinical trial will be performed in four intensive care units (ICUs) in the United States of America and Canada. Inclusion criteria include patients older than 21 years, in the first 48 h of mechanical ventilation (MV) and predicted to remain on the ventilator for at least 48 h. Patients with contraindications for phrenic nerve stimulation, severe chronic pulmonary diseases, or impossibility to measure diaphragm thickness with ultrasound will be excluded. Patients enrolled will be randomized to standard care (control) or 30-min daily non-invasive phrenic nerve stimulation up to 10 days after enrollment (intervention). The primary effectiveness endpoint is the change in diaphragm thickness on day 10, extubation, or death whichever occurs first. Secondary endpoints include change in diaphragm thickness on day 4, maximal inspiratory pressure before extubation, and time-to rapid shallow breathing index (RSBI) <105. Safety objectives include the proportion of device- or procedure-related adverse events (SAE). The estimated sample size will be 40 patients (20 per group). DISCUSSION: The STIMIT ACTIVATOR trial is a randomized multi-center study powered to elucidate whether non-invasive phrenic nerve stimulation is feasible, safe, and preserves diaphragm thickness. Meeting the primary endpoint will demonstrate its applicability in clinical practice to prevent diaphragmatic atrophy in ventilated patients. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05883163, August 29, 2023.
引用
- Schreiber AF, Subirà C, Sklar M, et al. Multi-center randomized superiority clinical trial in the early phase of mechanically ventilated patients to preserve diaphragm thickness using non-invasive magnetic phrenic nerve stimulation: STIMIT ACTIVATOR 1 pivotal trial. Trials. 2025. PMID: 40500715. doi:10.1186/s13063-025-08838-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。